A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Sponsor

AbbVie (Industry)

Overall Status

Completed

CT.gov ID

NCT03082209

Collaborator

(none)

153

Enrollment

Locations

Arms

58.1

Actual Duration (Months)

8.1

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies.

Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumors Cancer Hematologic Malignancies	Drug: ABBV-621 Drug: Venetoclax Drug: Bevacizumab Drug: FOLFIRI	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

153 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies

Actual Study Start Date :

Mar 20, 2017

Actual Primary Completion Date :

Jan 21, 2022

Actual Study Completion Date :

Jan 21, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI	Drug: ABBV-621 Intravenous (IV) Drug: Bevacizumab IV infusion Drug: FOLFIRI IV infusion
Experimental: Chemotherapy combination: ABBV-621+FOLFIRI Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.	Drug: ABBV-621 Intravenous (IV) Drug: FOLFIRI IV infusion
Experimental: Dose Optimization: ABBV-621 + Venetoclax for AML Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.	Drug: ABBV-621 Intravenous (IV) Drug: Venetoclax tablet, oral Other Names: ABT-199 GDC-0199
Experimental: Dose Optimization: ABBV-621 Monotherapy for AML Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.	Drug: ABBV-621 Intravenous (IV)
Experimental: Dose Optimization: ABBV-621 + Venetoclax for DLBCL Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.	Drug: ABBV-621 Intravenous (IV) Drug: Venetoclax tablet, oral Other Names: ABT-199 GDC-0199
Experimental: Dose Optimization for Pancreatic Cancer Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).	Drug: ABBV-621 Intravenous (IV)
Experimental: Dose Optimization for KRAS-mutant CRC Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.	Drug: ABBV-621 Intravenous (IV)
Experimental: Dose Escalation ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).	Drug: ABBV-621 Intravenous (IV)

Outcome Measures

Primary Outcome Measures

Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621 [Up to 21 days]
The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621
Area under the serum/plasma concentration time curve (AUC) of ABBV-621 [Up to 64 days]
Area under the serum/plasma concentration time curve (AUC) of ABBV-621.
Area under the serum/plasma concentration time curve (AUC) of Venetoclax [Up to 64 days]
Area under the serum/plasma concentration time curve (AUC) of venetoclax.
Maximum observed serum concentration (Cmax) of ABBV-621 [Up to 64 days]
Maximum observed serum concentration (Cmax) of ABBV-621.
Maximum observed serum concentration (Cmax) of Venetoclax [Up to 64 days]
Maximum observed serum concentration (Cmax) of venetoclax.
Time to Cmax (Tmax) of ABBV-621 [Up to 64 days]
Time to Cmax (Tmax) of ABBV-621.
Time to Cmax (Tmax) of Venetoclax [Up to 64 days]
Time to Cmax (Tmax) of ventoclax.
Terminal phase elimination rate constant (β) for ABBV-621 [Up to 64 days]
Terminal phase elimination rate constant (β) for ABBV-621.
Terminal phase elimination rate constant (β) for Venetoclax [Up to 64 days]
Terminal phase elimination rate constant (β) for venetoclax.
Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma [Up to 64 days]
Terminal phase elimination half-life (t1/2) for ABBV-621.
Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma [Up to 64 days]
Terminal phase elimination half-life (t1/2) for venetoclax.

Secondary Outcome Measures

QTcF Change from Baseline [Up to 64 days]
QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level
Number of Participants with Dose-limiting Toxicities (DLTs) [Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing < 5% blast count (whichever is later)]
Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in the Dose Optimization solid tumor cohorts must have either colorectal cancer with documented KRAS mutations (as determined by local testing), or pancreatic cancer (irrespective of mutational status). Participants in the chemotherapy combination cohorts must have metastatic or advanced unresectable colorectal cancer with documented RAS mutations (as determined by local testing).
Participant in dose escalation or dose optimization cohort must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies.
Participant in chemotherapy cohorts with CRC must have progressed after or failed to respond to initial systemic therapy.
Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
Must agree to provide the following samples for biomarker analysis:
All participants: archived tumor tissue (if available).
Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh tissue biopsies. (Note: fresh tissue biopsies will be optional for participants with solid tumor or NHL in Dose Escalation and will be collected only if consent is provided)
All participants with AML: pre- and on-treatment bone marrow aspirates (BMA)
Participants in chemotherapy combination cohorts: participants must provide a fresh biopsy if an archival biopsy is not available
Participant in chemotherapy cohorts with CRC must have confirmed RAS mutation
Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2. Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0
Must have adequate hematologic, renal and hepatic function.

Exclusion Criteria:

Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy. In addition, any AML participant identified through cerebrospinal fluid (CSF) analysis, as having active central nervous system (CNS) disease, will be excluded.
Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.
Receipt of any systemic anti-cancer agent, including investigational anti-cancer products, within 21 days prior to study drug administration or 3 half-lives, whichever is longer.
Participant with a history of cirrhosis or other indication of significant possible hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be discussed with the AbbVie TA MD before enrollment.
Participant with a positive diagnosis of hepatitis A, B, or C.
Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2 inhibitor
Dose Optimization combination cohorts only: Participant has received strong or moderate CYP3A inhibitors or inducers within 7 days prior to the initiation of study treatment.
Dose Optimization combination cohorts only: Participant has malabsorption syndrome or other condition that precludes enteral route of administration.
Dose Optimization combination cohorts only: Participant has promyelocytic leukemia (M3).
CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to first dose of study drug are excluded.
Participants in CRC chemotherapy combination cohort only: cardiomyopathy, coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty, pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within 1 year of first dose of study drug.
Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based chemotherapy.
Chemotherapy combination CRC participants only: Disease progression within 3-months of initiating first-line therapy.
Chemotherapy combination CRC participants only: history of Gilbert's syndrome or UG1T1A1 genotypes.
Chemotherapy combination with bevacizumab participants only: clinically significant conditions that may place the participant at higher risk with anti-angiogenic therapy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Yale University /ID# 158029	New Haven	Connecticut	United States	06510
2	The University of Chicago Medical Center /ID# 158030	Chicago	Illinois	United States	60637-1443
3	Ingalls Memorial Hosp /ID# 171221	Harvey	Illinois	United States	60426
4	Univ Michigan Med Ctr /ID# 207134	Ann Arbor	Michigan	United States	48109
5	Rhode Island Hospital /ID# 171157	Providence	Rhode Island	United States	02903
6	Vanderbilt University Medical Center /ID# 215000	Nashville	Tennessee	United States	37232-0011
7	MD Anderson Cancer Center /ID# 202187	Houston	Texas	United States	77030
8	Millennium Oncology /ID# 214981	Houston	Texas	United States	77090-1243
9	South Texas Accelerated Research Therapeutics /ID# 160574	San Antonio	Texas	United States	78229
10	Medical College of Wisconsin /ID# 171152	Milwaukee	Wisconsin	United States	53226-3522
11	National Cancer Center Hospital East /ID# 160596	Kashiwa-shi	Chiba	Japan	277-8577
12	Yamagata University Hospital /ID# 200681	Yamagata-shi	Yamagata	Japan	990-9585
13	Erasmus Medisch Centrum /ID# 160869	Rotterdam	Zuid-Holland	Netherlands	3015 GD
14	Universitair Medisch Centrum Groningen /ID# 169748	Groningen		Netherlands	9713 GZ
15	Maastricht Universitair Medisch Centrum /ID# 214935	Maastricht		Netherlands	6229 HX
16	Universitair Medisch Centrum Utrecht /ID# 169747	Utrecht		Netherlands	3584 CX
17	Hospital Universitario Vall d'Hebron /ID# 170809	Barcelona		Spain	08035
18	Hospital Universitario Fundacion Jimenez Diaz /ID# 200106	Madrid		Spain	28040
19	Hospital Universitario HM Sanchinarro /ID# 165136	Madrid		Spain	28050